Pharmacoeconomic review report: Ticagrelor (Brilinta)
Ticagrelor is an oral, direct-acting, selective and reversibly binding P2Y12 receptor antagonist that prevents adenosine diphosphate (ADP)-mediated P2Y12-dependent platelet activation and aggregation. The proposed new indication is ticagrelor, combined with low-dose (75 mg to 150 mg) acetylsalicylic...
| Corporate Author: | |
|---|---|
| Format: | eBook |
| Language: | English |
| Published: |
Ottawa (ON)
CADTH
2016, August 2016
|
| Series: | CADTH common drug review
|
| Subjects: | |
| Online Access: | |
| Collection: | National Center for Biotechnology Information - Collection details see MPG.ReNa |
Table of Contents:
- Includes bibliographical references